Cell Phone Technology Targeting ART Adherence and Drug Use (TXT-CBT)

This study is currently recruiting participants.
Verified July 2013 by University of California, Los Angeles
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Suzette Glasner-Edwards, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01884233
First received: May 24, 2013
Last updated: July 5, 2013
Last verified: July 2013

May 24, 2013
July 5, 2013
December 2012
March 2015   (final data collection date for primary outcome measure)
  • Substance Use Measures [ Time Frame: The ASI is to be collected at baseline (week 0), treatment-end (week 12), and Follow-Up (wek 24). UDS is collected weekly during the intervetion. ] [ Designated as safety issue: No ]
    • Addiction Severity Index (ASI) is an instrument widely used in addiction research to quantify drug use frequency and related problem areas.
    • Urine Drug Screen (UDS). Urine drug screens will be collected monthly using temperature controlled test cups. An FDA-approved one-step test will be used. During the 12-week treatment period, one full-screen panel and two panels only testing for opioids (heroin and prescription opioids) will be conducted. The UDS will test for the presence of: amphetamines, benzodiazepines, methadone, cocaine, methamphetamine, morphine (heroin), hydrocodone (Vicodin), oxycodone (OxyContin), and marijuana. The participants' change in substance use over time (as assessed by the ASI and UDS results) is being assessed from each timepoint to the next.
  • HIV Risk [ Time Frame: RBS will be collected at baseline (week 0), treatment-end (week 12), and FU (week 24) ] [ Designated as safety issue: No ]
    Risk Behavior Survey (RBS): The RBS (Darke et al., 1991) is a brief interview assessing involvement in HIV risk behaviors in the areas of drug use and sex in the previous 30 days. Additional items include whether the sexual partner uses or injects drugs. The participants' change in RBS scores is being assessed from each timepoint to the next.
  • Adherence Measures [ Time Frame: Pill bottle collection will be weekly during the intervention. Pill counts and Viral load will be collected at baseline (week 0), treatment end (week 12), and FU (week 24). ] [ Designated as safety issue: No ]
    • ART Adherence. We will use monthly phone-based unannounced pill counts (UPCs); Pharmacy information from pill bottles will also be collected to verify the number of pills dispensed between calls. Self-reported adherence will be assessed monthly using a brief adherence survey developed by Lu et al. Viral load will serve as a biological indicator of adherence. Consistent with the typical frequency with which viral load is assessed in clinical settings, data concerning viral load will be collected at baseline (week 0), treatment end (week 12), and FU (week 24) via chart review from the participant's medical provider. The participants' change in Adherence scores is being assessed from each timepoint to the next.
  • Substance Use Measures [ Time Frame: The ASI is to be collected at baseline (week 0), treatment-end (week 12), and Follow-Up (wek 24). UDS is collected weekly during the intervetion. ] [ Designated as safety issue: No ]
    • Addiction Severity Index (ASI) is an instrument widely used in addiction research to quantify drug use frequency and related problem areas.
    • Urine Drug Screen (UDS). Urine drug screens will be collected monthly using temperature controlled test cups. An FDA-approved one-step test will be used. During the 12-week treatment period, one full-screen panel and two panels only testing for opioids (heroin and prescription opioids) will be conducted. The UDS will test for the presence of: amphetamines, benzodiazepines, methadone, cocaine, methamphetamine, morphine (heroin), hydrocodone (Vicodin), oxycodone (OxyContin), and marijuana. The participants' change in ASI scores, and changes in UDS results, is being assessed from each timepoint to the next.
  • HIV Risk [ Time Frame: RBS will be collected at baseline (week 0), treatment-end (week 12), and FU (week 24) ] [ Designated as safety issue: No ]
    Risk Behavior Survey (RBS): The RBS (Darke et al., 1991) is a brief interview assessing involvement in HIV risk behaviors in the areas of drug use and sex in the previous 30 days. Additional items include whether the sexual partner uses or injects drugs. The participants' change in RBS scores is being assessed from each timepoint to the next.
  • Adherence Measures [ Time Frame: Pill bottle collection will be weekly during the intervention. Pill counts and Viral load will be collected at baseline (week 0), treatment end (week 12), and FU (week 24). ] [ Designated as safety issue: No ]
    • ART Adherence. We will use monthly phone-based unannounced pill counts (UPCs); Pharmacy information from pill bottles will also be collected to verify the number of pills dispensed between calls. Self-reported adherence will be assessed monthly using a brief adherence survey developed by Lu et al. Viral load will serve as a biological indicator of adherence. Consistent with the typical frequency with which viral load is assessed in clinical settings, data concerning viral load will be collected at baseline (week 0), treatment end (week 12), and FU (week 24) via chart review from the participant's medical provider. The participants' change in Adherence scores is being assessed from each timepoint to the next.
Complete list of historical versions of study NCT01884233 on ClinicalTrials.gov Archive Site
Quality of life [ Time Frame: week 0, week 12 and week 24 ] [ Designated as safety issue: No ]
We will collect data concerning health-related quality of life during and after treatment.
Same as current
Not Provided
Not Provided
 
Cell Phone Technology Targeting ART Adherence and Drug Use
Cell Phone Technology Targeting ART Adherence and Drug Use

The objective of the current research is to improve treatment for injection opioid users by augmenting buprenorphine pharmacotherapy with an innovative text-messaging strategy to promote relapse prevention skills, reduce HIV-risk behaviors, and improve HIV treatment regimen adherence.

the specific aims of this research are 1) To develop and refine, with user feedback, a cognitive behavioral therapy-based text-messaging intervention (TXT-CBT) for HIV-infected adults with opioid dependence; 2) To conduct a pilot randomized clinical trial to assess the feasibility of recruiting and retaining individuals for a large scale study and to determine the effect size of TXT-CBT over and above standard care (SC) on opioid use, HIV medication adherence, and healthcare outcomes. Both SC and SC+TXT-CBT participants will be assessed at baseline, treatment-end, and 12 weeks post-treatment; and 3) To examine potential mechanisms of action of TXT-CBT, including self-efficacy, affect regulation, and social support. The investigators hypothesize that TXT-CBT delivered in conjunction with SC will produce greater reductions in opioid use and HIV-risk behaviors, and will improve HIV treatment regimen adherence, relative to MM alone. Further, the investigators expect that SC+TXT-CBT will facilitate greater changes in negative affect, self-efficacy, and social support, and these changes will be associated with substance use outcomes. TXTCBT incorporates specific substance- and adherence-focused cognitive therapy techniques with a concurrent emphasis on reducing HIV-risk behaviors. By providing support to maximize HIV treatment regimen adherence, coupled with coping skills to address withdrawal symptoms and stress, two important factors in opioid relapse, TXT-CBT may provide a promising, cost-effective, and easily deployable augmenting strategy for the treatment of opioid users who are HIV-infected.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV
  • Opioid Abuse
  • Behavioral: Standard Care
    Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
  • Behavioral: Text Messaging CBT (TXT-CBT)
    Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
  • Experimental: Text Messaging CBT
    This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
    Interventions:
    • Behavioral: Standard Care
    • Behavioral: Text Messaging CBT (TXT-CBT)
  • Active Comparator: Standard Care
    Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
    Intervention: Behavioral: Standard Care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
June 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion criteria for participants in both Phase I and Phase II will be:

  1. Age 18 or older;
  2. DSM-IV diagnosis of Opioid Dependence;
  3. HIV-infected serostatus;
  4. Able to provide informed consent;
  5. Willing and able to participate in study procedures,
  6. Good general health or, in the case of a medical/psychiatric condition needing ongoing treatment, potential participant should be under the care of a physician who provides documented willingness to continue participant's medical management and coordinate care with the study physicians.

Exclusion Criteria:

  1. Lack of proficiency in English;
  2. Currently homeless (unless residing in a recovery home for which contact information can be provided);
  3. Dependence on an illicit substance for which medical detoxification is imminently needed.
  4. Presence of clinically significant psychiatric symptoms as assessed by MINI, such as psychosis, acute mania, or suicide risk that would require immediate treatment or make study compliance difficult.

    -

Both
18 Years and older
No
Contact: Anne B Lee, MSW 310-267-5232 abellows@mednet.ucla.edu
Contact: Suzette Glasner-Edwards, PhD 310-267-5206 sglasner@ucla.edu
United States
 
NCT01884233
1R34DA033196, 1R34DA033196
Yes
Suzette Glasner-Edwards, University of California, Los Angeles
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: Suzette Glasner-Edwards, PhD University of California, Los Angeles
University of California, Los Angeles
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP